Overview
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
Status:
Completed
Completed
Trial end date:
2006-01-01
2006-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's DiseasePhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- 30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn
& Yahr stage score of 2-5 in the "off" state.
Exclusion Criteria:
- Subjects with evidence or history of clinically significant hematological, renal,
endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
neurologic, or allergic disease (including drug allergies, but excluding untreated,
asymptomatic, seasonal allergies at time of dosing).